EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma

Kyoo Hyun Kim iD, Sungmin Cho, Yeyeong Jeong, Eun Sil Baek, Chung Lee, Hyang-Joo Ryu, Young Su Noh, Yoon-Hee Hong, Kee Yang Chung, Mi Ryung Roh, Byung Ho Oh, Chang Gon Kim und 2 weitere

The Oncologist · 03.06.2024 · 29 (6) · e811-e821

DOI: 10.1093/oncolo/oyae018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 12.03.2024. Verfasst von Kyoo Hyun Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Melanoma, Mutation, Proto-Oncogene Proteins B-raf, Isoquinolines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma incidence is on the rise in East Asia, yet studies of the molecular landscape are lacking in this population. We examined patients with melanoma who underwent next-generation sequencing (NGS) at a single tertiary center in South Korea, focusing on patients harboring NRAS or RAF alterations who received belvarafenib, a pan-RAF dimer inhibitor, through the Expanded Access Program (EAP). Patients and Methods Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023. Variant call format data were obtained and annotated. Patients in the EAP received 450 mg twice daily doses of belvarafenib.

Results

Alterations in the RAS/RTK pathway were the most prevalent, with BRAF and NRAS alteration rates of 22.4% and 17.7%, respectively. NGS enabled additional detection of fusion mutations, including 6 BRAF and 1 RAF1 fusion. Sixteen patients with NRAS or RAF alterations received belvarafenib through the EAP, and disease control was observed in 50%, with 2 patients demonstrating remarkable responses.

Conclusions

Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMutationProto-Oncogene Proteins B-rafIsoquinolinesPyrimidinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedGTP PhosphohydrolasesHigh-Throughput Nucleotide SequencingMembrane ProteinsProtein Kinase InhibitorsProto-Oncogene Proteins c-raf

Stichwörter der Autor:innen

RAF fusionbelvarafenibhigh-throughput nucleotide sequencingmelanoma

Substanzen

BRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-rafbelvarafenibIsoquinolinesPyrimidines

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Clinical Science, Deparment of Clinical Research and Development, Hanmi Pharm. Co., Ltd., Seoul, Republic of Korea.
  • Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.

ORCID-Profile: Kyoo Hyun Kim, Sang Joon Shin

Zitieren

APA

Kim, K. H., Cho, S., Jeong, Y., Baek, E. S., Lee, C., Ryu, H. J., Noh, Y. S., Hong, Y. H., Chung, K. Y., Roh, M. R., Oh, B. H., Kim, C. G., Jung, M., & Shin, S. J. (2024). Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma. The Oncologist, 29(6), e811-e821. https://doi.org/10.1093/oncolo/oyae018

Vancouver

Kim KH, Cho S, Jeong Y, Baek ES, Lee C, Ryu HJ, et al. Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma. The Oncologist. 2024;29(6):e811-e821. doi:10.1093/oncolo/oyae018

BibTeX
@article{Kim2024,
  author = {Kim, Kyoo Hyun and Cho, Sungmin and Jeong, Yeyeong and Baek, Eun Sil and Lee, Chung and Ryu, Hyang-Joo and Noh, Young Su and Hong, Yoon-Hee and Chung, Kee Yang and Roh, Mi Ryung and Oh, Byung Ho and Kim, Chang Gon and Jung, Minkyu and Shin, Sang Joon},
  title = {Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {6},
  pages = {e811--e821},
  doi = {10.1093/oncolo/oyae018}
}
Kostenlos starten →